Southwest China is home to China’s first mRNA vaccine production base against COVID-19. The recently established Yunnan Province in China is expected to be operational in October. The facility is expected to produce 200 million doses of the vaccine per year, bolstering the country’s mass vaccination campaign.
ARcoVax, an mRNA vaccine developed collaboratively by the Academy of Military Medical Sciences, Suzhou ABOGEN, and Yunnan Walvax Biotechnology Co is expected to enter mass production at the base in Yuxi, Yunnan Province.
When compared to mRNA vaccines developed in the United States and Germany, the domestic mRNA vaccine is much safer because the vaccine antigen target is more precisely selected and the neutralizing antibody induced is higher.
This vaccine has a lower storage cost than those from other countries because it is packaged in a single injection and can be stored at room temperature for a week or at 4 C for an extended period of time, making it easier to use.
The vaccine will be able to meet demand because the core materials and equipment for domestic mRNA vaccines are all manufactured domestically.
According to media reports, mRNA vaccines have the highest protection rate of 95 per cent among all vaccines in phase III clinical trials.
